علاج الالتهاب الرئوي البكتيري الآخر لدى البالغين المصابين بالتهاب رئوي مكتسب من المجتمع شديد الحدة

References

DOI: 10.1164/rccm.201908-1581ST

In inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, specific agents and doses are the same as 9.1):

Validated definition includes either one major criterion or three or more minor criteria.

a b-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or a b-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).

We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).

Failure to achieve clinical stability within 5 days is associated with higher mortality and worse clinical outcomes.